The efficacy and adverse events of arsenic trioxide for the patients with myelodysplastic syndrome: a systematic review and component network meta-analysis.
Xiaohua HuangYuan LiuRuixuan LiuXiaoqiu ZouHongyong YangPublished in: Hematology (Amsterdam, Netherlands) (2023)
ATO may be an effective and well-tolerant option for patients with myelodysplastic syndrome.